董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rob Faulkner | 男 | Director, Chairperson | 60 | 未披露 | 未持股 | 2023-04-14 |
| Glen Stettin | 男 | Director | 59 | 未披露 | 未持股 | 2023-04-14 |
| Michael Kramer | 男 | Director | 47 | 18.70万美元 | 未持股 | 2023-04-14 |
| Mark Doerr | 男 | Chief Executive Officer, President and Director | 53 | 252.44万美元 | 未持股 | 2023-04-14 |
| Laurie McGraw | 女 | Director | 59 | 未披露 | 未持股 | 2023-04-14 |
| Paul Johnson | 男 | Director | 38 | 22.50万美元 | 未持股 | 2023-04-14 |
| Laurie McGraw | 女 | Director | 59 | 21.80万美元 | 未持股 | 2023-04-14 |
| Glen Stettin | 男 | Director | 59 | 17.00万美元 | 未持股 | 2023-04-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Doerr | 男 | Chief Executive Officer, President and Director | 53 | 252.44万美元 | 未持股 | 2023-04-14 |
| Ramona Seabaugh | 女 | Chief Financial Officer, Treasurer and Secretary | 54 | 53.72万美元 | 未持股 | 2023-04-14 |
董事简历
中英对照 | 中文 | 英文- Rob Faulkner
-
Rob Faulkner自2020年11月起担任Medavail Holdings，Inc.董事会成员，自2022年1月起担任Medavail Holdings，Inc.董事长。Faulkner先生此前曾于2020年2月至2022年2月在MedAvail子公司董事会任职。自2023年4月起，福克纳先生还担任Augmedix, Inc.的董事会成员。自2021年10月起，福克纳先生还担任TERM0的董事会主席。Science 37 Holdings, Inc.福克纳先生自2008年2月起担任Redmile Group，LLC的董事总经理，该公司是一家专注于医疗保健的投资公司。在加入Redmile之前，福克纳先生曾担任16年的卖方股票分析师，从1992年到2008年，任职于Hambrecht & Quist（现为JPMorgan）、Thomas Weisel Partners（现为Stifel Financial Corp.）和SG Warburg & Co.（现为UBS）。福克纳先生拥有哈佛大学的A.B.学位和达特茅斯学院塔克商学院的MBA学位。
Rob Faulkner,has served on Medavail Holdings, Inc. board of directors since November 2020 and as Medavail Holdings, Inc. chairman since January 2022. Mr. Faulkner previously served on MedAvail Subsidiary's board of directors from February 2020 to February 2022. Since April 2023, Mr. Faulkner has also served on the board of directors of Augmedix, Inc. Since October 2021, Mr. Faulkner has also served as the Chairman of the board of directors of Science 37 Holdings, Inc. Mr. Faulkner has been a Managing Director at Redmile Group, LLC, a health care-focused investment firm, since February 2008. Prior to Redmile, Mr. Faulkner was a sell-side equity analyst for 16 years, from 1992 to 2008, including at Hambrecht & Quist (now JPMorgan), Thomas Weisel Partners (now Stifel Financial Corp.) and SG Warburg & Co. (now UBS). Mr. Faulkner holds an A.B. from Harvard College and an MBA from the Tuck School of Business at Dartmouth College. - Rob Faulkner自2020年11月起担任Medavail Holdings，Inc.董事会成员，自2022年1月起担任Medavail Holdings，Inc.董事长。Faulkner先生此前曾于2020年2月至2022年2月在MedAvail子公司董事会任职。自2023年4月起，福克纳先生还担任Augmedix, Inc.的董事会成员。自2021年10月起，福克纳先生还担任TERM0的董事会主席。Science 37 Holdings, Inc.福克纳先生自2008年2月起担任Redmile Group，LLC的董事总经理，该公司是一家专注于医疗保健的投资公司。在加入Redmile之前，福克纳先生曾担任16年的卖方股票分析师，从1992年到2008年，任职于Hambrecht & Quist（现为JPMorgan）、Thomas Weisel Partners（现为Stifel Financial Corp.）和SG Warburg & Co.（现为UBS）。福克纳先生拥有哈佛大学的A.B.学位和达特茅斯学院塔克商学院的MBA学位。
- Rob Faulkner,has served on Medavail Holdings, Inc. board of directors since November 2020 and as Medavail Holdings, Inc. chairman since January 2022. Mr. Faulkner previously served on MedAvail Subsidiary's board of directors from February 2020 to February 2022. Since April 2023, Mr. Faulkner has also served on the board of directors of Augmedix, Inc. Since October 2021, Mr. Faulkner has also served as the Chairman of the board of directors of Science 37 Holdings, Inc. Mr. Faulkner has been a Managing Director at Redmile Group, LLC, a health care-focused investment firm, since February 2008. Prior to Redmile, Mr. Faulkner was a sell-side equity analyst for 16 years, from 1992 to 2008, including at Hambrecht & Quist (now JPMorgan), Thomas Weisel Partners (now Stifel Financial Corp.) and SG Warburg & Co. (now UBS). Mr. Faulkner holds an A.B. from Harvard College and an MBA from the Tuck School of Business at Dartmouth College.
- Glen Stettin
-
Glen Stettin，自2020年11月起在Medavail Holdings，Inc.董事会任职。Stettin博士此前曾于2018年5月至2022年2月在MedAvail子公司董事会任职。Stettin博士目前在Evernorth担任高级副总裁兼首席创新官，Evernorth接替了信诺保险集团公司旗下的快捷药方公司，自2012年以来，他一直担任该公司的多个领导职务。在加入Express Scripts之前，Stettin博士曾在多个职能领域担任领导职务，包括1995年至2012年在Medco Health Solutions，Inc.的产品、技术、临床和运营。Stettin博士在加州大学旧金山分校完成了内科住院医师实习，在那里他还担任过莫菲特医院医疗首席住院医师和医疗服务助理主任，并且是加州大学旧金山分校/斯坦福大学的心脏病学研究员和罗伯特·伍德·约翰逊临床学者。他在利哈伊大学获得医学前科学学士学位，并在宾夕法尼亚医学院获得医学博士学位。
Glen Stettin,has served on Medavail Holdings, Inc. board of directors since November 2020. Dr. Stettin previously served on MedAvail Subsidiary's board of directors from May 2018 to February 2022. Dr. Stettin currently serves as Senior VP and Chief Innovation Officer at Evernorth which succeeded Express Scripts Holding Co., a subsidiary of Cigna Corporation, where he has held various leadership positions since 2012. Prior to Express Scripts, Dr. Stettin served in leadership roles in several functional areas, including product, technology, clinical and operations at Medco Health Solutions, Inc. from 1995 to 2012. Dr. Stettin completed his residency in internal medicine at the University of California, San Francisco, where he also served as medical chief resident and assistant chief of the medical service, Moffitt Hospital, and was a fellow in cardiology and Robert Wood Johnson Clinical Scholar at UCSF/Stanford. He received a B.A. in Premedical Sciences from Lehigh University and an M.D. from the Medical College of Pennsylvania. - Glen Stettin，自2020年11月起在Medavail Holdings，Inc.董事会任职。Stettin博士此前曾于2018年5月至2022年2月在MedAvail子公司董事会任职。Stettin博士目前在Evernorth担任高级副总裁兼首席创新官，Evernorth接替了信诺保险集团公司旗下的快捷药方公司，自2012年以来，他一直担任该公司的多个领导职务。在加入Express Scripts之前，Stettin博士曾在多个职能领域担任领导职务，包括1995年至2012年在Medco Health Solutions，Inc.的产品、技术、临床和运营。Stettin博士在加州大学旧金山分校完成了内科住院医师实习，在那里他还担任过莫菲特医院医疗首席住院医师和医疗服务助理主任，并且是加州大学旧金山分校/斯坦福大学的心脏病学研究员和罗伯特·伍德·约翰逊临床学者。他在利哈伊大学获得医学前科学学士学位，并在宾夕法尼亚医学院获得医学博士学位。
- Glen Stettin,has served on Medavail Holdings, Inc. board of directors since November 2020. Dr. Stettin previously served on MedAvail Subsidiary's board of directors from May 2018 to February 2022. Dr. Stettin currently serves as Senior VP and Chief Innovation Officer at Evernorth which succeeded Express Scripts Holding Co., a subsidiary of Cigna Corporation, where he has held various leadership positions since 2012. Prior to Express Scripts, Dr. Stettin served in leadership roles in several functional areas, including product, technology, clinical and operations at Medco Health Solutions, Inc. from 1995 to 2012. Dr. Stettin completed his residency in internal medicine at the University of California, San Francisco, where he also served as medical chief resident and assistant chief of the medical service, Moffitt Hospital, and was a fellow in cardiology and Robert Wood Johnson Clinical Scholar at UCSF/Stanford. He received a B.A. in Premedical Sciences from Lehigh University and an M.D. from the Medical College of Pennsylvania.
- Michael Kramer
-
Michael Kramer，自2020年11月起在Medavail Holdings，Inc.董事会任职。Kramer先生此前曾于2020年8月至2022年2月在MedAvail子公司董事会任职。自2021年5月以来，Kramer先生一直是Vensana Capital LLC的风险合伙人，该公司是一家专注于医疗保健的投资公司。从2017年到2021年4月，克莱默先生一直是CRG LP的运营合伙人，这是一家专注于医疗保健的投资公司，在那里他专注于医疗器械投资。从2017年9月到2021年4月，Kramer先生在Eximis Surgical，Inc.担任首席财务官，该公司是一家医疗器械公司，致力于开发在腹腔镜手术中进行微创标本切除的技术。从2016年2月到2017年2月，Kramer先生担任Endologix, Inc. TriVascular业务的首席运营官，该公司是一家专注于开发主动脉疾病微创技术的医疗设备公司。在TriVascular，Inc.被恩多勒吉克斯收购之前，2010年至2016年，Kramer先生担任TriVascular的首席财务官。2006年至2010年，Kramer先生在ATS Medical，Inc.担任过多个领导职务，该公司是一家专注于心脏手术的产品和服务的开发商和制造商，包括2007年至2010年担任ATS的首席财务官。克莱默此前还曾在安永会计师事务所（Ernst & Young LLP）担任鉴证和咨询服务业务经理。2018年8月至2020年8月，克莱默先生担任私营医疗设备公司Benvenue Medical，Inc.的执行董事长。克莱默先生在北达科他大学获得会计学学士学位。Kramer先生是注册会计师（非在职）。
Michael Kramer,has served on Medavail Holdings, Inc. board of directors since November 2020. Mr. Kramer previously served on MedAvail Subsidiary's board of directors from August 2020 to February 2022. Since May 2021, Mr. Kramer has been a Venture Partner at Vensana Capital LLC, a healthcare focused investment firm. From 2017 until April 2021, Mr. Kramer has been an Operating Partner at CRG LP, a healthcare-focused investment firm, where he focused on medical device investments. From September 2017 until April 2021, Mr. Kramer served as Chief Financial Officer for Eximis Surgical, Inc., a medical device company developing technology for performing minimally invasive specimen removal in laparoscopic surgery. From to February 2016 to February 2017, Mr. Kramer served as Chief Operating Officer of the TriVascular operations of Endologix, Inc., a medical device company focused on developing minimally invasive technologies for aortic disorders. Prior to TriVascular, Inc.'s acquisition by Endologix, from 2010 to 2016, Mr. Kramer served as TriVascular's Chief Financial Officer. From 2006 to 2010 Mr. Kramer held various leadership positions at ATS Medical, Inc., a developer and manufacturer of products and services focused on cardiac surgery, including serving as ATS's Chief Financial Officer from 2007 to 2010. Mr. Kramer also previously served as a manager in the assurance and advisory services practice at Ernst & Young LLP. From August 2018 to August 2020, Mr. Kramer served as Executive Chairman of Benvenue Medical, Inc., a private medical device company. Mr. Kramer received his Bachelor of Accountancy from the University of North Dakota. Mr. Kramer is a certified public accountant (inactive). - Michael Kramer，自2020年11月起在Medavail Holdings，Inc.董事会任职。Kramer先生此前曾于2020年8月至2022年2月在MedAvail子公司董事会任职。自2021年5月以来，Kramer先生一直是Vensana Capital LLC的风险合伙人，该公司是一家专注于医疗保健的投资公司。从2017年到2021年4月，克莱默先生一直是CRG LP的运营合伙人，这是一家专注于医疗保健的投资公司，在那里他专注于医疗器械投资。从2017年9月到2021年4月，Kramer先生在Eximis Surgical，Inc.担任首席财务官，该公司是一家医疗器械公司，致力于开发在腹腔镜手术中进行微创标本切除的技术。从2016年2月到2017年2月，Kramer先生担任Endologix, Inc. TriVascular业务的首席运营官，该公司是一家专注于开发主动脉疾病微创技术的医疗设备公司。在TriVascular，Inc.被恩多勒吉克斯收购之前，2010年至2016年，Kramer先生担任TriVascular的首席财务官。2006年至2010年，Kramer先生在ATS Medical，Inc.担任过多个领导职务，该公司是一家专注于心脏手术的产品和服务的开发商和制造商，包括2007年至2010年担任ATS的首席财务官。克莱默此前还曾在安永会计师事务所（Ernst & Young LLP）担任鉴证和咨询服务业务经理。2018年8月至2020年8月，克莱默先生担任私营医疗设备公司Benvenue Medical，Inc.的执行董事长。克莱默先生在北达科他大学获得会计学学士学位。Kramer先生是注册会计师（非在职）。
- Michael Kramer,has served on Medavail Holdings, Inc. board of directors since November 2020. Mr. Kramer previously served on MedAvail Subsidiary's board of directors from August 2020 to February 2022. Since May 2021, Mr. Kramer has been a Venture Partner at Vensana Capital LLC, a healthcare focused investment firm. From 2017 until April 2021, Mr. Kramer has been an Operating Partner at CRG LP, a healthcare-focused investment firm, where he focused on medical device investments. From September 2017 until April 2021, Mr. Kramer served as Chief Financial Officer for Eximis Surgical, Inc., a medical device company developing technology for performing minimally invasive specimen removal in laparoscopic surgery. From to February 2016 to February 2017, Mr. Kramer served as Chief Operating Officer of the TriVascular operations of Endologix, Inc., a medical device company focused on developing minimally invasive technologies for aortic disorders. Prior to TriVascular, Inc.'s acquisition by Endologix, from 2010 to 2016, Mr. Kramer served as TriVascular's Chief Financial Officer. From 2006 to 2010 Mr. Kramer held various leadership positions at ATS Medical, Inc., a developer and manufacturer of products and services focused on cardiac surgery, including serving as ATS's Chief Financial Officer from 2007 to 2010. Mr. Kramer also previously served as a manager in the assurance and advisory services practice at Ernst & Young LLP. From August 2018 to August 2020, Mr. Kramer served as Executive Chairman of Benvenue Medical, Inc., a private medical device company. Mr. Kramer received his Bachelor of Accountancy from the University of North Dakota. Mr. Kramer is a certified public accountant (inactive).
- Mark Doerr
-
Mark Doerr，自2022年1月起担任MedAvail Holdings, Inc.总裁兼首席执行官以及Medavail Holdings，Inc.董事会成员或成员。自2022年2月起，Doerr先生担任MedAvail子公司的总裁兼首席执行官和董事会成员。Doerr先生此前曾于2020年5月至2021年10月担任Change Healthcare（纳斯达克：Change Healthcare，Inc.）药房事业部高级副总裁兼总经理，并于2017年3月至2020年5月担任ERX Network，LLC（于2020年5月被TERM3，Inc.收购）的首席执行官。在此之前，Doerr先生担任过多个领导职务，例如2015年1月至2017年3月在Giant Eagle，Inc.担任药房高级副总裁，并于2009年3月至2014年12月在Adheris Health（前身为Catalina Health）担任高级合作伙伴和产品开发副总裁。Doerr先生获得了俄亥俄北方大学的药学学士学位。
Mark Doerr,has served as Medavail Holdings, Inc. President and Chief Executive Officer and a member or Medavail Holdings, Inc. board of directors since January 2022. Since February 2022, Mr. Doerr has served as President and Chief Executive Officer and on the board of directors of MedAvail Subsidiary. Mr. Doerr previously served as Senior Vice President, GM of Pharmacy Business Unit at Change Healthcare, Inc. (Nasdaq: CHNG) from May 2020 to October 2021 and as Chief Executive Officer of eRx Network, LLC (acquired by Change Healthcare, Inc. in May 2020) from March 2017 to May 2020. Prior to that, Mr. Doerr held various leadership roles such as Senior Vice President of Pharmacy at Giant Eagle, Inc. from January 2015 to March 2017 and as SVP Partnership & Product Development at Adheris Health (formerly, Catalina Health) from March 2009 to December 2014. Mr. Doerr received a B.S. in Pharmacy from Ohio Northern University. - Mark Doerr，自2022年1月起担任MedAvail Holdings, Inc.总裁兼首席执行官以及Medavail Holdings，Inc.董事会成员或成员。自2022年2月起，Doerr先生担任MedAvail子公司的总裁兼首席执行官和董事会成员。Doerr先生此前曾于2020年5月至2021年10月担任Change Healthcare（纳斯达克：Change Healthcare，Inc.）药房事业部高级副总裁兼总经理，并于2017年3月至2020年5月担任ERX Network，LLC（于2020年5月被TERM3，Inc.收购）的首席执行官。在此之前，Doerr先生担任过多个领导职务，例如2015年1月至2017年3月在Giant Eagle，Inc.担任药房高级副总裁，并于2009年3月至2014年12月在Adheris Health（前身为Catalina Health）担任高级合作伙伴和产品开发副总裁。Doerr先生获得了俄亥俄北方大学的药学学士学位。
- Mark Doerr,has served as Medavail Holdings, Inc. President and Chief Executive Officer and a member or Medavail Holdings, Inc. board of directors since January 2022. Since February 2022, Mr. Doerr has served as President and Chief Executive Officer and on the board of directors of MedAvail Subsidiary. Mr. Doerr previously served as Senior Vice President, GM of Pharmacy Business Unit at Change Healthcare, Inc. (Nasdaq: CHNG) from May 2020 to October 2021 and as Chief Executive Officer of eRx Network, LLC (acquired by Change Healthcare, Inc. in May 2020) from March 2017 to May 2020. Prior to that, Mr. Doerr held various leadership roles such as Senior Vice President of Pharmacy at Giant Eagle, Inc. from January 2015 to March 2017 and as SVP Partnership & Product Development at Adheris Health (formerly, Catalina Health) from March 2009 to December 2014. Mr. Doerr received a B.S. in Pharmacy from Ohio Northern University.
- Laurie McGraw
-
Laurie McGraw，自2022年1月起担任Medavail Holdings，Inc.董事会成员。自2022年3月起，McGraw女士还担任Augmedix（纳斯达克：AUGX）的董事会成员。从2016年2月到2022年3月，麦格劳女士担任美国医学协会下属部门Health Solutions的高级副总裁。从2013年6月到2015年3月，麦格劳女士担任Shareable Ink的首席执行官，该公司是一家提供临床文档和数据解决方案的私营公司。在此之前，麦格劳女士曾于2001年1月至2013年1月在AllScripts担任多个领导职务，包括首席客户官、战略客户总裁和企业解决方案总裁。麦格劳女士获得了布朗大学认知科学荣誉学士学位。
Laurie McGraw,has served as a member of Medavail Holdings, Inc. board of directors since January 2022. Since March 2022, Ms. McGraw has also served on the board of directors of Augmedix (Nasdaq: AUGX). From February 2016 until March 2022, Ms. McGraw has served as Senior Vice President of Health Solutions, a division of the American Medical Association. From June 2013 to March 2015, Ms. McGraw served as Chief Executive Officer of Shareable Ink, a private company providing clinical documentation and data solutions. Prior to that, Ms. McGraw served in various leadership roles at Allscripts including as Chief Client Officer, President of Strategic Accounts, and President of Enterprise Solutions, from January 2001 to January 2013. Ms. McGraw received a ScB with Honors in Cognitive Science from Brown University. - Laurie McGraw，自2022年1月起担任Medavail Holdings，Inc.董事会成员。自2022年3月起，McGraw女士还担任Augmedix（纳斯达克：AUGX）的董事会成员。从2016年2月到2022年3月，麦格劳女士担任美国医学协会下属部门Health Solutions的高级副总裁。从2013年6月到2015年3月，麦格劳女士担任Shareable Ink的首席执行官，该公司是一家提供临床文档和数据解决方案的私营公司。在此之前，麦格劳女士曾于2001年1月至2013年1月在AllScripts担任多个领导职务，包括首席客户官、战略客户总裁和企业解决方案总裁。麦格劳女士获得了布朗大学认知科学荣誉学士学位。
- Laurie McGraw,has served as a member of Medavail Holdings, Inc. board of directors since January 2022. Since March 2022, Ms. McGraw has also served on the board of directors of Augmedix (Nasdaq: AUGX). From February 2016 until March 2022, Ms. McGraw has served as Senior Vice President of Health Solutions, a division of the American Medical Association. From June 2013 to March 2015, Ms. McGraw served as Chief Executive Officer of Shareable Ink, a private company providing clinical documentation and data solutions. Prior to that, Ms. McGraw served in various leadership roles at Allscripts including as Chief Client Officer, President of Strategic Accounts, and President of Enterprise Solutions, from January 2001 to January 2013. Ms. McGraw received a ScB with Honors in Cognitive Science from Brown University.
- Paul Johnson
-
Paul Johnson，自2022年1月起担任Medavail Holdings，Inc.董事会成员。自2021年11月起，Johnson先生担任消费者遗传学和研究公司（“23andMe”）—— 23andMe控股有限公司（纳斯达克：ME）的副总裁、总经理、消费者。2013年11月至2021年11月，Johnson先生在在线健康公司Lemonaid Health（23andMe的子公司）担任过多个领导职务，包括2018年2月至2021年11月担任首席执行官，2015年6月至2018年2月担任联席首席执行官，2013年11月至2015年6月担任首席运营官。在此之前，Johnson先生曾担任Lloyds Pharmacy的在线主管和Zooplus AG的英国总监。约翰逊先生获得了伍斯特大学IT和商业管理荣誉学士学位。
Paul Johnson,has served as a member of Medavail Holdings, Inc. board of directors since January 2022. Since November 2021, Mr. Johnson has served as Vice President, General Manager, Consumer of 23andMe Holding Co. (Nasdaq: ME), a consumer genetics and research company ("23andMe"). From November 2013 to November 2021, Mr. Johnson served in various leadership roles at Lemonaid Health (a subsidiary of 23andMe), an online health company, including as Chief Executive Officer from February 2018 until November 2021, Co-Chief Executive Officer from June 2015 until February 2018, and Chief Operating officer from November 2013 until June 2015. Prior to that, Mr. Johnson served as Head of Online at Lloyds Pharmacy and as Director, UK at Zooplus AG. Mr. Johnson received a B.S. with honors in IT and Business Management from the University of Worcester. - Paul Johnson，自2022年1月起担任Medavail Holdings，Inc.董事会成员。自2021年11月起，Johnson先生担任消费者遗传学和研究公司（“23andMe”）—— 23andMe控股有限公司（纳斯达克：ME）的副总裁、总经理、消费者。2013年11月至2021年11月，Johnson先生在在线健康公司Lemonaid Health（23andMe的子公司）担任过多个领导职务，包括2018年2月至2021年11月担任首席执行官，2015年6月至2018年2月担任联席首席执行官，2013年11月至2015年6月担任首席运营官。在此之前，Johnson先生曾担任Lloyds Pharmacy的在线主管和Zooplus AG的英国总监。约翰逊先生获得了伍斯特大学IT和商业管理荣誉学士学位。
- Paul Johnson,has served as a member of Medavail Holdings, Inc. board of directors since January 2022. Since November 2021, Mr. Johnson has served as Vice President, General Manager, Consumer of 23andMe Holding Co. (Nasdaq: ME), a consumer genetics and research company ("23andMe"). From November 2013 to November 2021, Mr. Johnson served in various leadership roles at Lemonaid Health (a subsidiary of 23andMe), an online health company, including as Chief Executive Officer from February 2018 until November 2021, Co-Chief Executive Officer from June 2015 until February 2018, and Chief Operating officer from November 2013 until June 2015. Prior to that, Mr. Johnson served as Head of Online at Lloyds Pharmacy and as Director, UK at Zooplus AG. Mr. Johnson received a B.S. with honors in IT and Business Management from the University of Worcester.
- Laurie McGraw
-
Laurie McGraw，由于本公司收购IDX Systems Corporation的互联网子公司ChannelHealth的缘故，她于2001年1月加入Allscripts；目前是本公司的首席客户官。之前，她担任战略性客户总裁；此前，担任企业解决方案总裁。过去的15年，她一直在IDX 和 Allscripts从事临床自动化的工作，担任过执行、开发、服务部门的多个职务。她目前是TechAmerica的董事，及其商业部门委员会的成员。
Laurie McGraw,has served as a member of Medavail Holdings, Inc. board of directors since January 2022. Since March 2022, Ms. McGraw has also served on the board of directors of Augmedix (Nasdaq: AUGX). From February 2016 until March 2022, Ms. McGraw has served as Senior Vice President of Health Solutions, a division of the American Medical Association. From June 2013 to March 2015, Ms. McGraw served as Chief Executive Officer of Shareable Ink, a private company providing clinical documentation and data solutions. Prior to that, Ms. McGraw served in various leadership roles at Allscripts including as Chief Client Officer, President of Strategic Accounts, and President of Enterprise Solutions, from January 2001 to January 2013. Ms. McGraw received a ScB with Honors in Cognitive Science from Brown University. - Laurie McGraw，由于本公司收购IDX Systems Corporation的互联网子公司ChannelHealth的缘故，她于2001年1月加入Allscripts；目前是本公司的首席客户官。之前，她担任战略性客户总裁；此前，担任企业解决方案总裁。过去的15年，她一直在IDX 和 Allscripts从事临床自动化的工作，担任过执行、开发、服务部门的多个职务。她目前是TechAmerica的董事，及其商业部门委员会的成员。
- Laurie McGraw,has served as a member of Medavail Holdings, Inc. board of directors since January 2022. Since March 2022, Ms. McGraw has also served on the board of directors of Augmedix (Nasdaq: AUGX). From February 2016 until March 2022, Ms. McGraw has served as Senior Vice President of Health Solutions, a division of the American Medical Association. From June 2013 to March 2015, Ms. McGraw served as Chief Executive Officer of Shareable Ink, a private company providing clinical documentation and data solutions. Prior to that, Ms. McGraw served in various leadership roles at Allscripts including as Chief Client Officer, President of Strategic Accounts, and President of Enterprise Solutions, from January 2001 to January 2013. Ms. McGraw received a ScB with Honors in Cognitive Science from Brown University.
- Glen Stettin
-
Glen Stettin.Dr.， 2012年4月被任命为临床研究和新解决办法部门高级副总裁。2010年12月到2012年4月在美可保健公司担任高级副总裁兼首席医务官，并在2003年7月成为高级副总裁。2010年4月美可保健公司和快捷药方合并，他加入快捷药方公司。自1995年加入美可保健之后，在多个职能领域担任领导职位，包括产品、科技、临床和运营。
Glen Stettin,has served on Medavail Holdings, Inc. board of directors since November 2020. Dr. Stettin previously served on MedAvail Subsidiary's board of directors from May 2018 to February 2022. Dr. Stettin currently serves as Senior VP and Chief Innovation Officer at Evernorth which succeeded Express Scripts Holding Co., a subsidiary of Cigna Corporation, where he has held various leadership positions since 2012. Prior to Express Scripts, Dr. Stettin served in leadership roles in several functional areas, including product, technology, clinical and operations at Medco Health Solutions, Inc. from 1995 to 2012. Dr. Stettin completed his residency in internal medicine at the University of California, San Francisco, where he also served as medical chief resident and assistant chief of the medical service, Moffitt Hospital, and was a fellow in cardiology and Robert Wood Johnson Clinical Scholar at UCSF/Stanford. He received a B.A. in Premedical Sciences from Lehigh University and an M.D. from the Medical College of Pennsylvania. - Glen Stettin.Dr.， 2012年4月被任命为临床研究和新解决办法部门高级副总裁。2010年12月到2012年4月在美可保健公司担任高级副总裁兼首席医务官，并在2003年7月成为高级副总裁。2010年4月美可保健公司和快捷药方合并，他加入快捷药方公司。自1995年加入美可保健之后，在多个职能领域担任领导职位，包括产品、科技、临床和运营。
- Glen Stettin,has served on Medavail Holdings, Inc. board of directors since November 2020. Dr. Stettin previously served on MedAvail Subsidiary's board of directors from May 2018 to February 2022. Dr. Stettin currently serves as Senior VP and Chief Innovation Officer at Evernorth which succeeded Express Scripts Holding Co., a subsidiary of Cigna Corporation, where he has held various leadership positions since 2012. Prior to Express Scripts, Dr. Stettin served in leadership roles in several functional areas, including product, technology, clinical and operations at Medco Health Solutions, Inc. from 1995 to 2012. Dr. Stettin completed his residency in internal medicine at the University of California, San Francisco, where he also served as medical chief resident and assistant chief of the medical service, Moffitt Hospital, and was a fellow in cardiology and Robert Wood Johnson Clinical Scholar at UCSF/Stanford. He received a B.A. in Premedical Sciences from Lehigh University and an M.D. from the Medical College of Pennsylvania.
高管简历
中英对照 | 中文 | 英文- Mark Doerr
Mark Doerr，自2022年1月起担任MedAvail Holdings, Inc.总裁兼首席执行官以及Medavail Holdings，Inc.董事会成员或成员。自2022年2月起，Doerr先生担任MedAvail子公司的总裁兼首席执行官和董事会成员。Doerr先生此前曾于2020年5月至2021年10月担任Change Healthcare（纳斯达克：Change Healthcare，Inc.）药房事业部高级副总裁兼总经理，并于2017年3月至2020年5月担任ERX Network，LLC（于2020年5月被TERM3，Inc.收购）的首席执行官。在此之前，Doerr先生担任过多个领导职务，例如2015年1月至2017年3月在Giant Eagle，Inc.担任药房高级副总裁，并于2009年3月至2014年12月在Adheris Health（前身为Catalina Health）担任高级合作伙伴和产品开发副总裁。Doerr先生获得了俄亥俄北方大学的药学学士学位。
Mark Doerr,has served as Medavail Holdings, Inc. President and Chief Executive Officer and a member or Medavail Holdings, Inc. board of directors since January 2022. Since February 2022, Mr. Doerr has served as President and Chief Executive Officer and on the board of directors of MedAvail Subsidiary. Mr. Doerr previously served as Senior Vice President, GM of Pharmacy Business Unit at Change Healthcare, Inc. (Nasdaq: CHNG) from May 2020 to October 2021 and as Chief Executive Officer of eRx Network, LLC (acquired by Change Healthcare, Inc. in May 2020) from March 2017 to May 2020. Prior to that, Mr. Doerr held various leadership roles such as Senior Vice President of Pharmacy at Giant Eagle, Inc. from January 2015 to March 2017 and as SVP Partnership & Product Development at Adheris Health (formerly, Catalina Health) from March 2009 to December 2014. Mr. Doerr received a B.S. in Pharmacy from Ohio Northern University.- Mark Doerr，自2022年1月起担任MedAvail Holdings, Inc.总裁兼首席执行官以及Medavail Holdings，Inc.董事会成员或成员。自2022年2月起，Doerr先生担任MedAvail子公司的总裁兼首席执行官和董事会成员。Doerr先生此前曾于2020年5月至2021年10月担任Change Healthcare（纳斯达克：Change Healthcare，Inc.）药房事业部高级副总裁兼总经理，并于2017年3月至2020年5月担任ERX Network，LLC（于2020年5月被TERM3，Inc.收购）的首席执行官。在此之前，Doerr先生担任过多个领导职务，例如2015年1月至2017年3月在Giant Eagle，Inc.担任药房高级副总裁，并于2009年3月至2014年12月在Adheris Health（前身为Catalina Health）担任高级合作伙伴和产品开发副总裁。Doerr先生获得了俄亥俄北方大学的药学学士学位。
- Mark Doerr,has served as Medavail Holdings, Inc. President and Chief Executive Officer and a member or Medavail Holdings, Inc. board of directors since January 2022. Since February 2022, Mr. Doerr has served as President and Chief Executive Officer and on the board of directors of MedAvail Subsidiary. Mr. Doerr previously served as Senior Vice President, GM of Pharmacy Business Unit at Change Healthcare, Inc. (Nasdaq: CHNG) from May 2020 to October 2021 and as Chief Executive Officer of eRx Network, LLC (acquired by Change Healthcare, Inc. in May 2020) from March 2017 to May 2020. Prior to that, Mr. Doerr held various leadership roles such as Senior Vice President of Pharmacy at Giant Eagle, Inc. from January 2015 to March 2017 and as SVP Partnership & Product Development at Adheris Health (formerly, Catalina Health) from March 2009 to December 2014. Mr. Doerr received a B.S. in Pharmacy from Ohio Northern University.
- Ramona Seabaugh
Ramona Seabaugh，自2021年9月起担任MedAvail Holdings, Inc.首席财务官。Seabaugh女士还担任MedAvail子公司的首席财务官、财务主管和秘书以及董事会成员，以及MedAvail Holdings，Inc.药房子公司MedAvail Pharmacy，Inc.（“SpotRx”）的总裁、首席财务官、秘书和董事会成员。在此之前，Seabaugh女士分别于2021年2月至2021年9月在Vixxo担任财务副总裁，并于2019年7月至2021年2月在Ascension Health担任财务副总裁，并于2014年3月至2019年7月在邦纳 Health担任药房服务首席财务官。Seabaugh女士获得了威斯康星大学Parkside分校的金融学士学位和Lake Forest管理研究生院的工商管理硕士学位。
Ramona Seabaugh,has served as Medavail Holdings, Inc. Chief Financial Officer since September 2021. Ms. Seabaugh also serves as Chief Financial Officer, Treasurer and Secretary and on the board of directors of MedAvail Subsidiary, as well as President, Chief Financial Officer, Secretary and on the board of directors of MedAvail Pharmacy, Inc. ("SpotRx"), Medavail Holdings, Inc. pharmacy subsidiary. Prior to that, Ms. Seabaugh served as VP of Finance at Vixxo from February 2021 to September 2021 and at Ascension Health from July 2019 to February 2021, respectively, and as Chief Financial Officer of Pharmacy Services at Banner Health from March 2014 to July 2019. Ms. Seabaugh received a B.S. in Finance from the University of Wisconsin Parkside and an M.B.A. from Lake Forest Graduate School of Management.- Ramona Seabaugh，自2021年9月起担任MedAvail Holdings, Inc.首席财务官。Seabaugh女士还担任MedAvail子公司的首席财务官、财务主管和秘书以及董事会成员，以及MedAvail Holdings，Inc.药房子公司MedAvail Pharmacy，Inc.（“SpotRx”）的总裁、首席财务官、秘书和董事会成员。在此之前，Seabaugh女士分别于2021年2月至2021年9月在Vixxo担任财务副总裁，并于2019年7月至2021年2月在Ascension Health担任财务副总裁，并于2014年3月至2019年7月在邦纳 Health担任药房服务首席财务官。Seabaugh女士获得了威斯康星大学Parkside分校的金融学士学位和Lake Forest管理研究生院的工商管理硕士学位。
- Ramona Seabaugh,has served as Medavail Holdings, Inc. Chief Financial Officer since September 2021. Ms. Seabaugh also serves as Chief Financial Officer, Treasurer and Secretary and on the board of directors of MedAvail Subsidiary, as well as President, Chief Financial Officer, Secretary and on the board of directors of MedAvail Pharmacy, Inc. ("SpotRx"), Medavail Holdings, Inc. pharmacy subsidiary. Prior to that, Ms. Seabaugh served as VP of Finance at Vixxo from February 2021 to September 2021 and at Ascension Health from July 2019 to February 2021, respectively, and as Chief Financial Officer of Pharmacy Services at Banner Health from March 2014 to July 2019. Ms. Seabaugh received a B.S. in Finance from the University of Wisconsin Parkside and an M.B.A. from Lake Forest Graduate School of Management.